Elyse Swallow
Vice President
Boston
Education
M.P.P. and M.A., economics, Duke University
Summary of Experience
Ms. Swallow specializes in health care consulting, with a specific focus on health economics and outcomes research. She has conducted research on hepatitis C, cancer, and rare genetic diseases. Her work has involved clinical trial data analyses, retrospective claims analyses, patient chart reviews, and economic modeling. Recent projects include evaluating the impact of formulary policies, informing clinical trial design, estimating the comparative safety and efficacy of alternative therapies, analyzing treatment patterns, and assessing the clinical characteristics and economic burden of various illnesses.
Selected Cases
Selected Publishing
-
The additional costs per month of progression-free survival and overall survival: An economic model comparing everolimus with cabozantinib, nivolumab, and axitinib for second-line treatment of metasta
Journal of Managed Care and Specialty Pharmacy. 01 Apr 2018;24(4):335-343c.
2018Swallow E, Messali A, Ghate S, McDonald E, Duchesneau E, Perez JR
-
Real-World Economic Outcomes During Time on Treatment Among Patients Who Initiated Sunitinib or Pazopanib as First Targeted Therapy for Advanced Renal Cell Carcinoma: A Retrospective Analysis of Medicare Claims Data
Journal of Managed Care & Specialty Pharmacy, 2018 Jun;24(6):525-533
2018Vogelzang NJ, Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N
-
Epilepsy treatment patterns among patients with tuberous sclerosis complex
Journal of the Neurological Sciences. 2018 Aug 15;391:104-108
2018Song J, Swallow E, Said Q, Peeples M, Meiselbach M, Signorovitch J, Kohrman M, Korf B, Krueger D, Wong M, Sparagana S
-
Patterns of Disease Monitoring and Treatment Among Patients With Tuberous Sclerosis Complex-related Angiomyolipomas
Urology. Jun 2017;104:110-114
2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S
-
Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea
Asia-Pacific Journal of Clinical Oncology. Oct 2017;13(5):e239-e245
2017Lim SH, Yoh KA, Lee JS, Ahn MJ, Kim YJ, Kim SH, Zhang J, Patel D, Swallow E, Kageleiry A, Galebach P, Lee D, Stein K, Degun R, Park K
-
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER-Medicare Database Analysis
Clinical Genitourinary Cancer. Aug 2017;15(4):e573-e582
2017Pal SK, Ghate SR, Li N, Swallow E, Peeples M, Zichlin ML, Perez JR, Agarwal N, Vogelzang NJ
-
Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?
Cns Drugs. Oct 2017;31(10):899-910
2017Swallow E, Fang A, Signorovitch J, Plumb J, Borghs S
-
Clinical and Economic Outcomes in Elderly Advanced Renal Cell Carcinoma Patients Starting Pazopanib or Sunitinib Treatment: A Retrospective Medicare Claims Analysis
Advances in Therapy. Nov 2017;34(11):2452-2465
2017Vogelzang NJ, Pal SK, Ghate SR, Swallow E, Li N, Peeples M, Zichlin ML, Meiselbach MK, Perez JR, Agarwal N
-
Patterns of Disease Monitoring and Treatment Among Patients with Tuberous Sclerosis Complex-related (1)
Urology. Jun 2017;104:110-114
2017Swallow E, King S, Song J, Peeples M, Signorovitch JE, Liu Z, Prestifilippo J, Frost M, Kohrman M, Korf B, Krueger D, Sparagana S
-
Categorizing natural history trajectories of ambulatory function measured by the 6-minute walk distance in patients with Duchenne muscular dystrophy
Neuromuscuarl Disorders, 2016 05. e-pub ahead of print 2016/07/18; doi: 10.1016/j.nmd.2016.05.016.
2016Mercuri E, Signorovitch J, Swallow E, Song J, Ward SJ.
-
Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison
Journal of Comparative Effectiveness Research, 2016 03; 5(2): 129-139. e-pub ahead of print 2015/09/22
2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Mu F, Kim S, Noviello S, Signorovitch J.
-
Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison
Clinical Therapeutics, 2016 02; 38(2): 404-412. e-pub ahead of print 2016/02/04
2016Swallow E, Song J, Yuan Y, Kalsekar A, Kelley C, Peeples M, Mu F, Ackerman P, Signorovitch J.
-
Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular D(1)
PLOS ONE, 2016 Oct 13;11(10):e0164684
2016Goemans N, Vanden Hauwe M, Signorovitch J, Swallow E, Song J
-
Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies
PLoS One. 2014 Dec 10;9(12):e114264
2014Heng DY, Signorovitch J, Swallow E, Li N, Zhong Y, Qin P, Zhuo DY, Wang X, Park J, Stergiopoulos S, Kollmannsberger C
-
Real-world adherence and persistence associated with nebivolol or hydrochlorothiazide as add-on treatment for hypertension
Curr Med Res Opin. 2014 Apr;30(4):637-43
2014Chen S, Macaulay D, Swallow E, Diener M, Farooqui S, Xie J, Wu EQ
-
Real-world patterns of endocrine therapy for metastatic hormone-receptor-positive (HR+)/human epidermal growth factor receptor-2-negative (HER2-) breast cancer patients in the United States: 2002-2012
Curr Med Res Opin. 2014 Aug;30(8):1537-45
2014Swallow E, Zhang J, Thomason D, Tan RD, Kageleiry A, Signorovitch J
-
Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison
Exp Hematol Oncol. 2013 Dec 6;2(1):32
2013Signorovitch J, Swallow E, Kantor E, Wang X, Klimovsky J, Haas T, Devine B, Metrakos P
-
A pulmonary exacerbation risk score among cystic fibrosis patients not receiving recommended care
Pediatr Pulmonol. 2013 Oct;48(10):954-61
2012Sawicki GS, Ayyagari R, Zhang J, Signorovitch JE, Fan L, Swallow E, Latremouille-Viau D, Wu EQ, Shi L
-
Comparative efficacy of vildagliptin and sitagliptin in Japanese patients with type 2 diabetes: a matching-adjusted indirect comparison of randomized trials
Clin Drug Investig. 2011;31(9):665-74. doi: 10.2165/11592490-000000000-00000.
2011Signorovitch J, Wu EQ, Swallow E, Kantor E, Fan L, Gruenberger J